Based mostly on trial findings, U.S. Meals and Drug Administration (FDA) approval of the Insightec system was prolonged in November to deal with moderate-to-severe motor problems, similar to tremors, stiffness and dyskinesia (involuntary motion), in superior illness sufferers who fail to answer normal Parkinson’s therapies.
Learn extra here.
